tbuckley/cabot-search huggingface dataset:
Real‐world effectiveness of intensive chemotherapy with 7&amp;3 versus venetoclax and hypomethylating agent in acute myeloid leukemia
Authors: Andrew H. Matthews, Alexander E. Perl, Selina M. Luger, Saar I. Gill, Catherine Lai, David L. Porter, Sarah Skuli, Ximena Jordan Bruno, Martin P. Carroll, Craig W. Freyer, Alison Carulli, Daria V. Babushok, Noelle V. Frey, Elizabeth O. Hexner, Mary Ellen Martin, Shannon R. McCurdy, Edward A. Stadtmauer, Alison W. Loren, Vikram R. Paralkar, Ivan P. Maillard, Keith W. Pratz
Journal: American Journal of Hematology (2023)

Abstract Intensive chemotherapy with cytarabine and anthracycline (7&amp;3) remains the standard therapy for patients medically fit for induction, but the assessment of fitness remains controversial. Venetoclax and hypomethylating agent (ven/HMA) combination therapy has improved outcomes in unfit patients but no prospective study has assessed ven/HMA versus 7&amp;3 as initial therapy in older, fit patients. Given no studies and expectation of ven/HMA use in patients outside of trial criteria, we evaluated retrospective outcomes among newly diagnosed patients. A nationwide electronic health record (EHR)‐derived database and the University of Pennsylvania EHR identified 312 patients receiving 7&amp;3 and 488 receiving ven/HMA who were 60–75 years old without history of organ failure. Ven/HMA patients were older and more likely to have secondary AML, adverse cytogenetics, and adverse mutations. Median overall survival (OS) for patients receiving intensive chemotherapy was 22 versus 10 months for ven/HMA (HR 0.53, 95% CI 0.40–0.60). Controlling for measured baseline characteristic imbalances reduced survival advantage by half (HR 0.71, 95% CI 0.53–0.94). A sub‐group of patients with equipoise, likelihood at least 30%–70% of receiving either treatment, had similar OS outcomes (HR 1.10, 95% CI 0.75–1.6). Regarding safety outcomes, 60‐day mortality was higher for ven/HMA (15% vs. 6% at 60 days) despite higher documented infections and febrile neutropenia for 7&amp;3. In this multicenter real‐word dataset, patients selected for intensive chemotherapy had superior OS but a large group had similar outcomes with ven/HMA. Prospective randomized studies, controlling for both measured and unmeasured confounders, must confirm this outcome.
Venous Thrombosis Accelerates Atherosclerosis in Mice
Authors: Prakash Saha, Clemens Gutmann, Jack Kingdon, Alexandru Dregan, Laura Bertolaccini, Steven P. Grover, Ashish S. Patel, Bijan Modarai, Oliver Lyons, Christian Schulz, Marcelo E. Andia, Alkystis Phinikaridou, René M. Botnar, Alberto Smith
Journal: Circulation (2023)
Prognostic impact of cardiac resynchronization therapy guided by phase analysis: a CZT study
Authors: Riccardo Liga, Umberto Startari, Davide Spatafora, Erica Michelotti, Alessia Gimelli
Journal:  (2023)

Abstract Aims To evaluate whether phase analysis imaging may predict treatment response and long-term prognosis after cardiac resynchronization therapy (CRT). Methods and results Sixty-nine patients underwent myocardial perfusion imaging followed by CRT. Patients with ischaemic heart disease and non-ischaemic cardiomyopathy (NICM) were identified. Left ventricular (LV) mechanical dyssynchrony (LVMD) was assessed at phase analysis and the region of the latest mechanical activation was identified. LV pacing lead position was considered ‘concordant’ when located in the region of the latest mechanical activation, and ‘discordant’ otherwise. The ‘6 months post-CRT’/‘baseline’ ratio of LV ejection fraction was computed as a measure of CRT response. LVMD was revealed in 47/69 patients, 27 of whom (57%) had a concordant LV lead implantation. Only concordant pacing was associated with LV functional improvement (ejection fraction ratio: 1.28 ± 0.25 vs. 1.11 ± 0.32 in discordant stimulation, P = 0.028). However, this relationship persisted only in patients with NICM (P &amp;lt; 0.001), while it disappeared in those with ischaemic heart disease (P = NS). Twenty-eight events occurred during 30 ± 21 months follow-up. While discordant LV lead location was the major predictor of unfavourable prognosis (hazard ratio 3.29, 95% confidence interval 1.25–8.72; P = 0.016), this relationship was confirmed only in patients with NICM. Conclusions Phase analysis of myocardial perfusion imaging may guide CRT implantation, identifying patients who would most likely benefit from this procedure.
Association between estimated cardiorespiratory fitness and breast cancer: a prospective cohort study
Authors: Rebecca A G Christensen, Julia A Knight, Rinku Sutradhar, Jennifer D Brooks
Journal: British Journal of Sports Medicine (2023)

Objective To examine the association between cardiorespiratory fitness (CRF) and the risk of breast cancer in postmenopausal women. Methods This study used data from 17 840 cancer-free postmenopausal women with a CRF assessment from the UK Biobank. High estimated CRF (eCRF) was categorised as being &gt; 80th percentile within 10-year age bands. Fine and Gray regression was used to examine the association between eCRF and breast cancer risk, accounting for both non-breast cancer diagnoses and all-cause mortality as competing risks. Age was used as the time scale. Several different models were produced, including those adjusting for known breast cancer risk factors, and stratified by measures of body fat (body mass index and per cent body fat). Results Over a median follow-up of 11.0 years there were 529 cases of invasive breast cancer, 1623 cases of non-breast cancer disease and 241 deaths. With adjustment for breast cancer risk factors, high eCRF was associated with a 24% (subdistribution HR (SDHR) 0.76, 95% CI 0.60 to 0.97) lower risk of breast cancer. When stratified by measures of body fat, we found evidence of effect measure modification. Mainly, having high eCRF was only associated with a lower risk of breast cancer among those classified as having overweight/obesity (SDHR 0.33, 95% CI 0.11 to 1.01) or percentage body fat above the 1st quintile (SDHR 0.65, 95% CI 0.45 to 0.94). Conclusion Having higher CRF may be a protective factor against breast cancer in postmenopausal women but only for women with elevated body fat.
Individual glioblastoma cells harbor both proliferative and invasive capabilities during tumor progression
Authors: Miriam Ratliff, Kianush Karimian-Jazi, Dirk C Hoffmann, Laurèl Rauschenbach, Matthias Simon, Ling Hai, Henriette Mandelbaum, Marc C Schubert, Tobias Kessler, Stefanie Uhlig, Daniel Dominguez Azorin, Erik Jung, Matthias Osswald, Gergely Solecki, Máté E Maros, Varun Venkataramani, Martin Glas, Nima Etminan, Björn Scheffler, Wolfgang Wick, Frank Winkler
Journal: Neuro-Oncology (2023)

Abstract Background Glioblastomas are characterized by aggressive and infiltrative growth, and by striking heterogeneity. The aim of this study was to investigate whether tumor cell proliferation and invasion are interrelated, or rather distinct features of different cell populations. Methods Tumor cell invasion and proliferation were longitudinally determined in real-time using 3D in vivo 2-photon laser scanning microscopy over weeks. Glioblastoma cells expressed fluorescent markers that permitted the identification of their mitotic history or their cycling versus non-cycling cell state. Results Live reporter systems were established that allowed us to dynamically determine the invasive behavior, and previous or actual proliferation of distinct glioblastoma cells, in different tumor regions and disease stages over time. Particularly invasive tumor cells that migrated far away from the main tumor mass, when followed over weeks, had a history of marked proliferation and maintained their proliferative capacity during brain colonization. Infiltrating cells showed fewer connections to the multicellular tumor cell network, a typical feature of gliomas. Once tumor cells colonized a new brain region, their phenotype progressively transitioned into tumor microtube-rich, interconnected, slower-cycling glioblastoma cells. Analysis of resected human glioblastomas confirmed a higher proliferative potential of tumor cells from the invasion zone. Conclusions The detection of glioblastoma cells that harbor both particularly high proliferative and invasive capabilities during brain tumor progression provides valuable insights into the interrelatedness of proliferation and migration—2 central traits of malignancy in glioma. This contributes to our understanding of how the brain is efficiently colonized in this disease.
Clinical Characteristics and Outcomes Among Travelers With Severe Dengue
Authors: Ralph Huits, Kristina M. Angelo, Bhawana Amatya, Sapha Barkati, Elizabeth D. Barnett, Emmanuel Bottieau, Hannah Emetulu, Loïc Epelboin, Gilles Eperon, Line Medebb, Federico Gobbi, Martin P. Grobusch, Oula Itani, Sabine Jordan, Paul Kelly, Karin Leder, Marta Díaz-Menéndez, Nobumasa Okumura, Aisha Rizwan, Camilla Rothe, Mauro Saio, Jesse Waggoner, Yukihiro Yoshimura, Michael Libman, Davidson H. Hamer, Eli Schwartz
Journal: Annals of Internal Medicine (2023)

Dengue virus is a flavivirus transmitted by
Acupuncture and Doxylamine–Pyridoxine for Nausea and Vomiting in Pregnancy
Authors: Xiao-Ke Wu, Jing-Shu Gao, Hong-Li Ma, Yu Wang, Bei Zhang, Zhao-Lan Liu, Jian Li, Jing Cong, Hui-Chao Qin, Xin-Ming Yang, Qi Wu, Xiao-Yong Chen, Zong-Lin Lu, Ya-Hong Feng, Xue Qi, Yan-Xiang Wang, Lan Yu, Ying-Mei Cui, Chun-Mei An, Li-Li Zhou, Yu-Hong Hu, Lu Li, Yi-Juan Cao, Ying Yan, Li Liu, Yu-Xiu Liu, Zhi-Shun Liu, Rebecca C. Painter, Ernest H.Y. Ng, Jian-Ping Liu, Ben Willem J. Mol, Chi Chiu Wang
Journal: Annals of Internal Medicine (2023)

An effective and safe treatment for nausea and vomiting of pregnancy (NVP) is lacking.
Integrative metabolomics science in Alzheimer’s disease: Relevance and future perspectives
Authors: Simone Lista, Raúl González-Domínguez, Susana López-Ortiz, Álvaro González-Domínguez, Héctor Menéndez, Juan Martín-Hernández, Alejandro Lucia, Enzo Emanuele, Diego Centonze, Bruno P. Imbimbo, Viviana Triaca, Luana Lionetto, Maurizio Simmaco, Miroslava Cuperlovic-Culf, Jericha Mill, Lingjun Li, Mark Mapstone, Alejandro Santos-Lozano, Robert Nisticò
Journal: Ageing Research Reviews (2023)
Mortality in Patients With Ebstein Anomaly
Authors: Filip Eckerström, Mikael Dellborg, Vibeke Elisabeth Hjortdal, Peter Eriksson, Zacharias Mandalenakis
Journal: Journal of the American College of Cardiology (2023)

Low birth prevalence and referral bias constitute significant obstacles to elucidating the natural history of Ebstein anomaly (EA).An extensive 2-country register-based collaboration was performed to investigate the mortality in patients with EA.Patients born from 1970 to 2017 and diagnosed with EA were identified in Danish and Swedish nationwide medical registries. Each patient was matched by birth year and sex with 10 control subjects from the general population. Cumulative mortality and HR of mortality were computed using Kaplan-Meier failure function and Cox proportional regression model.The study included 530 patients with EA and 5,300 matched control subjects with a median follow-up of 11 years. In the EA cohort, 43% (228) underwent cardiac surgery. Cumulative mortality was lower for patients diagnosed in the modern era (the year 2000 and later) than for those diagnosed in the prior era (P < 0.001). Patients with isolated lesion displayed lower cumulative mortality than patients with complex lesions did (P < 0.001). Patients with a presumed mild EA anatomy displayed a 35-year cumulative mortality of 11% (vs 4% for the matched control subjects; P < 0.001), yielding an HR for mortality of 6.0 (95% CI: 2.7-13.6), whereas patients with presumed severe EA demonstrated an HR of 36.2 (95% CI: 15.5-84.4) compared with control subjects and a cumulative mortality of 18% 35 years following diagnosis.Mortality in patients with EA is high irrespective of presence of concomitant congenital cardiac malformations and time of diagnosis compared with the general population, but overall mortality has improved in the contemporary era.
Intrahepatic and Periduodenal Embolization for Protein-Losing Enteropathy Patients With Congenital Heart Disease
Authors: Ari J. Gartenberg, Ganesh Krishnamurthy, Abhay Srinivasan, Fernando A. Escobar, Jefferson N. Brownell, Petar Mamula, Michael L. O’Byrne, Yoav Dori, Christopher L. Smith
Journal: Journal of the American College of Cardiology (2023)
The Student
Authors: Lauren Posego
Journal: Annals of Internal Medicine (2023)

Ad LibitumJune 2023The StudentLauren Posego, BALauren Posego, BASidney Kimmel Medical College Philadelphia, PennsylvaniaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M22-3515 Audio Reading - “The Student” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “The Student” by Lauren Posego, BA Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The student knocks quietly at your doorevery morning before the sun is up,after the nurses have checked your vitalsq4h throughout the night,after the residents have performeda full neurologic exam—hammering at the kneespush, pull, open, close“Do you feel this pin I’m pricking you with?”The student comes into do it all over again.The student asks, “Do you have any questions?”and replies, “Let me ask the resident”to each one.While everyone in the ... Author, Article, and Disclosure InformationAuthors: Lauren Posego, BAAffiliations: Sidney Kimmel Medical College Philadelphia, PennsylvaniaCorresponding Author: Lauren Posego, BA; e-mail, laposego@gmail.com. PreviousarticleNextarticle Advertisement Audio Reading - “The Student” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “The Student” by Lauren Posego, BA Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics June 2023Volume 176, Issue 6Page: 876 ePublished: 20 June 2023 Issue Published: June 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Magician, With Parkinson’s
Authors: Terri Kirby Erickson
Journal: Annals of Internal Medicine (2023)

Ad LibitumJune 2023Magician, With Parkinson’sTerri Kirby Erickson, BATerri Kirby Erickson, BAPfafftown, North CarolinaSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/M22-3490 Audio Reading - “Magician, With Parkinson’s” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Magician, With Parkinson’s” by Terri Kirby Erickson, BA Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Wasn’t easy, anymore, to pull the rabbits ... Author, Article, and Disclosure InformationAuthors: Terri Kirby Erickson, BAAffiliations: Pfafftown, North CarolinaCorresponding Author: Terri Kirby Erickson, BA; e-mail, [email protected]rr.com. PreviousarticleNextarticle Advertisement Audio Reading - “Magician, With Parkinson’s” Audio. Michael A. Lacombe, MD, Annals Associate Editor, reads “Magician, With Parkinson’s” by Terri Kirby Erickson, BA Your browser does not support the audio element. Audio player progress bar Step backward in current audio track Play current audio trackPause current audio track Step forward in current audio track Mute current audio trackUnmute current audio track 00:00/ FiguresReferencesRelatedDetails Metrics Current IssueJune 2023Volume 176, Issue 6Page: 875 ePublished: 20 June 2023 Issue Published: June 2023 Copyright & PermissionsCopyright © 2023 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Malignant blue nevus: Characterization of US epidemiology and prognostic factors of a rare neoplasm with aggressive clinical course using the Surveillance, Epidemiology, and End Results Program database
Authors: Sara Yumeen, Fatima N Mirza, Humza N Mirza, Cheryl K Zogg, Jonathan S Leventhal, Jeffrey M Cohen
Journal: Journal of the American Academy of Dermatology (2023)
Performance measurement part II: A guide to developing dermatology performance measures
Authors: Daniella Reimann, Dillon Imbriano, Tatiana Abrantes, Janet Sullivan, Oliver Wisco, Stephanie Chan, Christopher Dimarco, Nicole Gehret, Nicole Grenier, Paul Imbriano, Benjamin Kahn, Leonardo Lizbinski, Cathy Massoud, Nicole Negbenebor, Sylvia Parra, Deven Patel, Margo Reeder, Allison Robbins, Junko Takeshita, Eric J. Yang, Stephanie C. Braxton, Dirk Elston
Journal: Journal of the American Academy of Dermatology (2023)
Preventing occludin tight-junction disruption via inhibition of microRNA-193b-5p attenuates viral load and influenza-induced lung injury
Authors: Chirag M. Vaswani, Amir K. Varkouhi, Sahil Gupta, Amin M. Ektesabi, James N. Tsoporis, Sadiya Yousef, Pamela J. Plant, Adriana L. da Silva, Yuchen Cen, Yi-Chieh Tseng, Sabrina S. Batah, Alexandre T. Fabro, Suzanne L. Advani, Andrew Advani, Howard Leong-Poi, John C. Marshall, Cristiana C. Garcia, Patricia R.M. Rocco, Guillermo M. Albaiceta, Steffen Sebastian-Bolz, Tania H. Watts, Theo J. Moraes, Vera L. Capelozzi, Claudia.C. dos Santos
Journal: Molecular Therapy (2023)

Virus-induced lung injury is associated with loss of pulmonary epithelial-endothelial tight junction integrity. While the alveolar-capillary membrane may be an indirect target of injury, viruses may interact directly and/or indirectly with miRs to augment their replication potential and evade the host antiviral defense system. Here, we expose how the influenza virus (H1N1) capitalizes on host-derived interferon-induced, microRNA (miR)-193b-5p to target occludin and compromise antiviral defenses. Lung biopsies from patients infected with H1N1 revealed increased miR-193b-5p levels, marked reduction in occludin protein, and disruption of the alveolar-capillary barrier. In C57BL/6 mice, the expression of miR-193b-5p increased, and occludin decreased, 5-6 days post-infection with influenza (PR8). Inhibition of miR-193b-5p in primary human bronchial, pulmonary microvascular, and nasal epithelial cells enhanced antiviral responses. miR-193b-deficient mice were resistant to PR8. Knockdown of occludin, both in vitro and in vivo, and overexpression of miR-193b-5p reconstituted susceptibility to viral infection. miR-193b-5p inhibitor mitigated loss of occludin, improved viral clearance, reduced lung edema, and augmented survival in infected mice. Our results elucidate how the innate immune system may be exploited by the influenza virus and how strategies that prevent loss of occludin and preserve tight junction function may limit susceptibility to virus-induced lung injury.
Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly
Authors: Zoe K. McQuilten, Le Thi Phuong Thao, Sant-Rayn Pasricha, Andrew S. Artz, Michael Bailey, Andrew T. Chan, Harvey Jay Cohen, Jessica E. Lockery, Anne M. Murray, Mark R. Nelson, Hans G. Schneider, Rory Wolfe, Robyn L. Woods, Erica M. Wood, John J. McNeil
Journal: Annals of Internal Medicine (2023)

Daily low-dose aspirin increases major bleeding; however, few studies have investigated its effect on iron deficiency and anemia.
Comments on ‘Insight into the history and trends of surgical simulation training in education: a bibliometric analysis’
Authors: Yongbin He, Haifeng Tang, Haiyang Wu, Guoxin Ni
Journal: International Journal of Surgery (2023)

aSchool of Sport Medicine and Rehabilitation, Beijing Sport University, Beijing, China bDepartment of Spine Surgery, Tianjin Huanhu Hospital, Graduate School of Tianjin Medical University, Tianjin, China cDuke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina, USA dDepartment of Rehabilitation Medicine, The First Affiliated Hospital of Xiamen University, Xiamen, China The data underlying this article will be shared by the corresponding author on reasonable request. Yongbin He, Haifeng Tang These authors have contributed equally to this work and share the first authorship. Sponsorships or competing interests that may be relevant to content are disclosed at the end of this article *Corresponding author. Address: E-mail address: [email protected] (G. Ni). *Corresponding author. Address: Duke University, Durham, NC UNITED STATES. E-mail address: [email protected] (H. Wu). Supplemental Digital Content is available for this article. Direct URL citations are provided in the HTML and PDF versions of this article on the journal's website, www.journal-surgery.net. Published online ■ ■ This is an open access article distributed under the Creative Commons Attribution-ShareAlike License 4.0, which allows others to remix, tweak, and build upon the work, even for commercial purposes, as long as the author is credited and the new creations are licensed under the identical terms. http://creativecommons.org/licenses/by-sa/4.0/
Assessment of Atherothrombotic Risk in Patients With Type 2 Diabetes Mellitus
Authors: David D. Berg, Filipe A. Moura, Andrea Bellavia, Benjamin M. Scirica, Stephen D. Wiviott, Deepak L. Bhatt, Itamar Raz, Erin A. Bohula, Robert P. Giugliano, Jeong-Gun Park, Mark W. Feinberg, Eugene Braunwald, David A. Morrow, Marc S. Sabatine
Journal: Journal of the American College of Cardiology (2023)

Risk of atherothrombotic events is not uniform in patients with type 2 diabetes mellitus (T2DM). Tailored risk assessment may help guide selection of pharmacotherapies for cardiovascular primary and secondary prevention. The purpose of this study was to develop a risk model for atherothrombosis in patients with T2DM. We developed and validated a risk model for myocardial infarction (MI) or ischemic stroke (IS) in a pooled cohort of 42,181 patients with T2DM from 4 TIMI (Thrombolysis In Myocardial Infarction) clinical trial cohorts. Candidate variables were assessed with multivariable Cox regression, and independent variables (P < 0.05) were retained in the final model. Discrimination and calibration were assessed. Treatment interactions with dapagliflozin (sodium-glucose cotransporter-2 inhibitor) and evolocumab (proprotein convertase subtilisin/kexin type 9 inhibitor) were explored in the DECLARE-TIMI 58 (Dapagliflozin Effect on CardiovascuLAR Events-Thrombolysis In Myocardial Infarction 58) and FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trials, respectively. Sixteen variables were independent predictors of MI or IS. The model identified a >8-fold gradient of MI or IS rates between the top vs bottom risk quintiles in the validation cohort (3-year Kaplan-Meier rate: 14.9% vs 1.4%; P < 0.0001). C-indexes were 0.704 and 0.706 in the derivation and validation cohorts, respectively. The model was well-calibrated in both primary and secondary prevention. Absolute reduction in the rates of MI or IS tended to be greater in patients with higher baseline predicted risk for both dapagliflozin (absolute risk reduction: 2.1% vs 0.2%) and evolocumab (absolute risk reduction: 3.2% vs 1.0%). We developed and validated a risk score for atherothrombotic events, leveraging 16 routinely assessed clinical variables in patients with T2DM. The score has the potential to improve risk assessment and inform clinical decision-making.